PMID- 36158675
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220928
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Real-world experience with anti-programmed cell death protein 1 immunotherapy in 
      patients with esophageal cancer: A retrospective single-center study.
PG  - 880053
LID - 10.3389/fonc.2022.880053 [doi]
LID - 880053
AB  - The "real-world" data of programmed cell death protein 1 (PD-1) inhibitors in 
      esophageal cancer (EPC) are still an unmet medical need, including the clinical 
      efficacy and safety. Seventy-seven EPC data were studied retrospectively; the 
      progression-free survival (PFS), risk factors (clinical stages larger than stage 
      II, metastatic sites larger than 2, treatment lines larger than the first line, 
      previous surgical treatment, combined positive score [CPS] expression, etc.), and 
      the safety were analyzed. The median PFS for all patients was 7.2 months, 
      clinical stage > stage II; the number of treatment lines > first line was 
      significantly correlated with prognosis (all P < 0.05). Subgroup analysis showed 
      that the median PFS of patients with clinical stage </= II was better; the results 
      were the same for the patients with </=2 metastatic sites, first-line PD-1 
      inhibitors, and not previously received radical surgery (all P < 0.05). 
      Meanwhile, the incidence of adverse events (AEs) of varying degrees was 25.97% 
      (20/77) in 20 patients and 6.49% (5/77) of grade 3/4 AEs. The highest AE was 
      myelosuppression (15.58%), followed by liver function injury (7.79%). In 
      addition, >/=2 lines of treatment and >2 metastatic sites predicted poor outcomes 
      for patients with EPC who had failed first-line therapy or progressed with the 
      combined immunotherapy and chemotherapy treatment strategy (all P < 0.05).
CI  - Copyright (c) 2022 Wang, Cai, Wu, Li, Zhu, Lin, Yan, Mo, Luo and Fu.
FAU - Wang, Xinpeng
AU  - Wang X
AD  - Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, 
      Fujian Medical University, Fuzhou, China.
AD  - Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of 
      Medicine, Xiamen University, Xiamen, China.
FAU - Cai, Lvjuan
AU  - Cai L
AD  - Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, 
      Fujian Medical University, Fuzhou, China.
AD  - Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of 
      Medicine, Xiamen University, Xiamen, China.
FAU - Wu, Mengjing
AU  - Wu M
AD  - Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, 
      Fujian Medical University, Fuzhou, China.
AD  - Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of 
      Medicine, Xiamen University, Xiamen, China.
FAU - Li, Guo
AU  - Li G
AD  - Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, 
      Fujian Medical University, Fuzhou, China.
AD  - Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of 
      Medicine, Xiamen University, Xiamen, China.
FAU - Zhu, Yunyun
AU  - Zhu Y
AD  - Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, 
      Fujian Medical University, Fuzhou, China.
AD  - Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of 
      Medicine, Xiamen University, Xiamen, China.
FAU - Lin, Xinyue
AU  - Lin X
AD  - Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, 
      Fujian Medical University, Fuzhou, China.
AD  - Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of 
      Medicine, Xiamen University, Xiamen, China.
FAU - Yan, Xue
AU  - Yan X
AD  - Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, 
      Fujian Medical University, Fuzhou, China.
AD  - Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of 
      Medicine, Xiamen University, Xiamen, China.
FAU - Mo, Peng
AU  - Mo P
AD  - Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, 
      Fujian Medical University, Fuzhou, China.
AD  - Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of 
      Medicine, Xiamen University, Xiamen, China.
FAU - Luo, Huachun
AU  - Luo H
AD  - Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, 
      Fujian Medical University, Fuzhou, China.
AD  - Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of 
      Medicine, Xiamen University, Xiamen, China.
FAU - Fu, Zhichao
AU  - Fu Z
AD  - Department of Radiotherapy, The 900th Hospital of the Joint Logistics Team, 
      Fujian Medical University, Fuzhou, China.
AD  - Department of Radiotherapy, Dongfang Hospital of Xiamen University, School of 
      Medicine, Xiamen University, Xiamen, China.
LA  - eng
PT  - Journal Article
DEP - 20220909
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9500415
OTO - NOTNLM
OT  - efficiency
OT  - esophageal cancer
OT  - immunotherapy
OT  - retrospective study
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/09/27 06:00
MHDA- 2022/09/27 06:01
PMCR- 2022/01/01
CRDT- 2022/09/26 17:24
PHST- 2022/02/20 00:00 [received]
PHST- 2022/08/17 00:00 [accepted]
PHST- 2022/09/26 17:24 [entrez]
PHST- 2022/09/27 06:00 [pubmed]
PHST- 2022/09/27 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.880053 [doi]
PST - epublish
SO  - Front Oncol. 2022 Sep 9;12:880053. doi: 10.3389/fonc.2022.880053. eCollection 
      2022.